Human CellExp™ BCMA / TNFRSF17, human recombinant
TNFRSF17, CD269, BCM, BCMA
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q02223 |
---|---|
Calculated MW | 7.5 kDa |
Gene ID | 608 |
---|---|
Other Names | TNFRSF17, CD269, BCM, BCMA |
Gene Source | Human |
Source | HEK 293 cells |
Assay&Purity | SDS-PAGE;≥90% |
Recombinant | Yes |
Target/Specificity | CD269 |
Application Notes | Reconstitute in sterile deionized water to a concentration of 50 µg/ml. |
Format | Lyophilized |
Storage | -20°C;Lyophilized from 0.22 µm filtered solution in PBS, pH7.4. Generally Mannitol or Trehalose is added as a protectant before lyophilization. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) is also known as B-cell maturation protein (BCMA), CD antigen CD269, which is a member of the TNF-receptor superfamily. TNFRSF17 contains one TNFR-Cys repeat. TNFRSF17 is expressed in mature B-cells, but not in T-cells or monocytes. TNFRSF17 is receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. TNFRSF17 promotes B-cell survival and plays a role in the regulation of humoral immunity. TNFRSF17 can activate NF-kappa-B and JNK.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.